- Urea breath tests, used primarily for the diagnosis of Helicobacter pylori infections, are gaining significant traction due to their non-invasive nature, high accuracy, and rapid results. These diagnostic tools are becoming increasingly vital components of gastrointestinal disease management in both clinical and point-of-care settings
- The escalating demand for urea breath tests is primarily fueled by the rising global burden of H. pylori infections, increased awareness regarding early diagnosis of gastric disorders, and the growing preference for non-invasive, patient-friendly diagnostic solutions
- North America dominated the urea breath test market with the largest revenue share of 38.6% in 2024, attributed to advanced healthcare infrastructure, high awareness levels among patients, and favorable reimbursement policies. The U.S. in particular is witnessing strong growth due to technological advancements, increasing outpatient diagnostic volumes, and growing adoption of non-invasive tests
- Asia-Pacific is expected to register the fastest CAGR of 11.4% during the forecast period (2025–2032), driven by expanding healthcare access, rising disposable incomes, and increasing investments in diagnostic technologies in countries such as China, India, and Japan. The rising prevalence of gastrointestinal diseases and initiatives for mass screening are further boosting regional demand
- The Point-of-Care Tests (POCT) segment dominated the market with a revenue share of 59.5% in 2024, driven by the rising demand for rapid and accessible diagnostic solutions, particularly in outpatient clinics and remote care environments. Its convenience, faster turnaround time, and ease of use are significantly enhancing its adoption across various healthcare settings globally
